AbbVie Inc. (NYSE:ABBV) Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,080 shares of the company’s stock after selling 265 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in AbbVie were worth $3,924,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of ABBV. Seelaus Asset Management LLC lifted its holdings in shares of AbbVie by 16.5% in the 4th quarter. Seelaus Asset Management LLC now owns 5,107 shares of the company’s stock valued at $908,000 after buying an additional 725 shares during the period. Counterweight Ventures LLC raised its position in AbbVie by 3.4% in the fourth quarter. Counterweight Ventures LLC now owns 20,271 shares of the company’s stock worth $3,602,000 after acquiring an additional 675 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its holdings in AbbVie by 8.5% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 89,190 shares of the company’s stock valued at $15,849,000 after acquiring an additional 6,967 shares during the period. Apollon Wealth Management LLC boosted its position in shares of AbbVie by 11.6% during the 4th quarter. Apollon Wealth Management LLC now owns 79,230 shares of the company’s stock worth $14,079,000 after purchasing an additional 8,209 shares in the last quarter. Finally, Opinicus Capital Inc. grew its stake in shares of AbbVie by 5.2% during the 4th quarter. Opinicus Capital Inc. now owns 9,217 shares of the company’s stock worth $1,638,000 after purchasing an additional 458 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

AbbVie stock opened at $190.67 on Friday. The stock has a fifty day moving average price of $177.54 and a 200 day moving average price of $185.60. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $207.32. The firm has a market capitalization of $336.94 billion, a P/E ratio of 79.45, a PEG ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter last year, the business posted $2.79 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.32 earnings per share for the current year.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ABBV. Leerink Partners raised shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price objective on the stock in a report on Friday, November 22nd. Piper Sandler boosted their price target on AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Truist Financial raised their price objective on AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Guggenheim upped their target price on AbbVie from $212.00 to $214.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Leerink Partnrs raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.